Additionally, our study reveals a novel molecular regulatory circuit driving cisplatin resistance in BLCA: ARHGEF12 activates the PI3K–Akt axis by modulating the RhoA/ROCK pathway, thereby promoting resistance in BLCA cells. The gene discussed is AKT1; the disease is bladder transitional cell carcinoma.